Mid-term treatment-related cognitive sequelae in glioma patients.
Glioma
NeuroCog FX
Neuropsychological assessment
Prospective
Treatment-related neurotoxicity
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
11
04
2022
accepted:
21
05
2022
pubmed:
8
7
2022
medline:
29
7
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
Cognitive functioning represents an essential determinant of quality of life. Since significant advances in neuro-oncological treatment have led to prolonged survival it is important to reliably identify possible treatment-related neurocognitive dysfunction in brain tumor patients. Therefore, the present study specifically evaluates the effects of standard treatment modalities on neurocognitive functions in glioma patients within two years after surgery. Eighty-six patients with World Health Organization (WHO) grade 1-4 gliomas were treated between 2004 and 2012 and prospectively followed within the German Glioma Network. They received serial neuropsychological assessment of attention, memory and executive functions using the computer-based test battery NeuroCog FX. As the primary outcome the extent of change in cognitive performance over time was compared between patients who received radiotherapy, chemotherapy or combined radio-chemotherapy and patients without any adjuvant therapy. Additionally, the effect of irradiation and chemotherapy was assessed in subgroup analyses. Furthermore, the potential impact of the extent of tumor resection and histopathological characteristics on cognitive functioning were referred to as secondary outcomes. After a median of 16.8 (range 5.9-31.1) months between post-surgery baseline neuropsychological assessment and follow-up assessment, all treatment groups showed numerical and often even statistically significant improvement in all cognitive domains. The extent of change in cognitive functioning showed no difference between treatment groups. Concerning figural memory only, irradiated patients showed less improvement than non-irradiated patients (p = 0.029, η Within a two-year post-surgery interval, radiotherapy, chemotherapy or their combination as standard treatment did not have a detrimental effect on cognitive functions in WHO grade 1-4 glioma patients. Cognitive performance in patients with adjuvant treatment was comparable to that of patients without.
Identifiants
pubmed: 35796933
doi: 10.1007/s11060-022-04044-1
pii: 10.1007/s11060-022-04044-1
pmc: PMC9325813
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-79Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Neurology. 2002 Jul 9;59(1):40-8
pubmed: 12105305
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Neuro Oncol. 2020 Sep 29;22(9):1388-1398
pubmed: 32107555
J Clin Oncol. 2003 Oct 1;21(19):3557-8
pubmed: 12913103
J Clin Oncol. 2004 May 1;22(9):1583-8
pubmed: 15051755
J Neurooncol. 2012 Jun;108(2):285-90
pubmed: 22350376
Lancet Neurol. 2009 Sep;8(9):810-8
pubmed: 19665931
Neurosurgery. 2021 Nov 18;89(6):945-953
pubmed: 33586764
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1175-83
pubmed: 15964709
J Clin Oncol. 2013 Nov 10;31(32):4076-84
pubmed: 24101048
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Br J Cancer. 2004 May 4;90(9):1691-6
pubmed: 15150608
Neurology. 2003 Apr 8;60(7):1113-8
pubmed: 12682316
Fortschr Neurol Psychiatr. 2006 Nov;74(11):643-50
pubmed: 17103364
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e487-93
pubmed: 22209148
Neurology. 2004 Feb 24;62(4):548-55
pubmed: 14981169
J Neurooncol. 2010 Dec;100(3):427-37
pubmed: 20449630
Epilepsy Behav. 2009 Oct;16(2):298-310
pubmed: 19733124
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
J Clin Oncol. 2003 Jul 1;21(13):2519-24
pubmed: 12829670
Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):527-33
pubmed: 8655376
J Clin Oncol. 2014 Feb 20;32(6):535-41
pubmed: 24419119
Lancet Oncol. 2016 Nov;17(11):1533-1542
pubmed: 27686943
Qual Life Res. 1996 Feb;5(1):139-50
pubmed: 8901377
Neurology. 2000 Apr 11;54(7):1442-8
pubmed: 10751254
Neurology. 2002 Jul 9;59(1):121-3
pubmed: 12105319
J Clin Oncol. 2012 Sep 1;30(25):3065-70
pubmed: 22851558
Lancet. 2002 Nov 2;360(9343):1361-8
pubmed: 12423981
Neurology. 2001 May 22;56(10):1285-90
pubmed: 11376174
Neuro Oncol. 2011 Jun;13(6):660-8
pubmed: 21558074
J Neurooncol. 2008 Feb;86(3):321-7
pubmed: 17926007
J Neurooncol. 2014 Jan;116(2):387-94
pubmed: 24264531
Cancer. 2003 Feb 1;97(3):649-56
pubmed: 12548607
Neuro Oncol. 2021 Jan 30;23(1):23-33
pubmed: 32623467
Neuro Oncol. 2003 Apr;5(2):89-95
pubmed: 12672280
J Neurooncol. 2019 Sep;144(3):511-518
pubmed: 31342318
Cell Rep. 2020 Apr 14;31(2):107500
pubmed: 32294436
Nat Rev Clin Oncol. 2009 Oct;6(10):596-603
pubmed: 19707193
Science. 2003 Dec 5;302(5651):1760-5
pubmed: 14615545
Acta Oncol. 2020 Sep;59(9):1091-1097
pubmed: 32847475
Ann Oncol. 2007 Jul;18(7):1145-51
pubmed: 17284616
Neurosurg Clin N Am. 2019 Jan;30(1):27-34
pubmed: 30470402
Lancet. 2009 Nov 7;374(9701):1639-51
pubmed: 19897130
Nat Med. 2002 Sep;8(9):955-62
pubmed: 12161748